The first production run gets all the attention. But the mistake that kills more supplement brands isn't the first run — it's the second one.
Here's the pattern: a brand runs 5,000 units per flavor. It sells through in 90 days. The founders are excited. The obvious move is to scale up: run 50,000 units next time, get the per-unit cost down, build inventory ahead of demand. This is the decision that ends more brands than any production failure, any co-packer problem, or any compliance issue.
Why the second run feels safe when it isn't
The first 90 days of a new product are almost never representative of steady-state demand. Early sales are driven by your personal network, your launch marketing, the novelty effect among early adopters, and the specific timing of any influencer mentions or press coverage. These are real sales — but they may not repeat.
The metric that tells you whether your product has real legs isn't first-purchase volume. It's reorder rate. For a consumable supplement product, the question that matters is: how many people who bought once came back for a second purchase within 60 days? If your reorder rate is below 30%, you have a product that people try and don't keep. Tripling your production run doesn't fix that.
The reorder rate calculation
Take the number of customers who made a first purchase in month one. Count how many of them made a second purchase by the end of month two. That percentage is your reorder rate. It's imperfect — some customers buy larger quantities upfront, some buy on different cycles — but it's the earliest signal of whether you have a retention problem.
A reorder rate above 40% for a supplement product is a strong signal. Below 30% is a warning sign worth understanding before you scale production. Below 20% means something is wrong with either the product or the expectation you're setting at point of purchase, and more inventory won't solve it.
The channel-specific velocity problem
First-run velocity through DTC doesn't predict Amazon velocity. First-run velocity to your existing audience doesn't predict cold traffic conversion. If your growth plan involves new channels, new audiences, or new retail accounts, those are different demand environments with different velocity profiles. Don't project DTC sell-through onto an Amazon launch, and don't project your first-run sell-through onto a retail placement without actual retailer sell-through data.
The shelf life trap
Production decisions made in month two have to be sold through before the product's shelf life creates a problem. Most retailers won't accept product with less than 6 months of remaining shelf life. If your product has an 18-month shelf life, you're effectively working with a 12-month sell window for retail channels.
Run the math before you commit to volume: how many units do you need to sell per month to clear the production run before it hits the 6-month remaining shelf life threshold? If that number requires a velocity you haven't demonstrated, the run size is too big.
The smart scaling sequence
The right scaling sequence for a supplement brand is incremental and evidence-driven:
5,000 units per flavor → confirm sell-through and reorder rate → 10,000 units per flavor → confirm velocity holds at higher volume → 20,000 units per flavor → confirm channel expansion is working → 50,000 units per flavor.
Each step proves the next one is warranted. Each step keeps your capital at risk manageable. Each step gives you an off-ramp if something needs to change — a formula tweak, a label update, a packaging requirement from a new retailer — without writing off six figures of inventory.
The brands that scale successfully are the ones that treat each production run as a hypothesis test, not a commitment. The hypothesis: at this volume, I can sell through this inventory before it ages out, while maintaining unit economics that work. Prove the hypothesis before you double the bet.
What to check before your second run
- First-run sell-through rate — what percentage of units sold and how quickly?
- Reorder rate — what percentage of first-time buyers came back?
- Channel-specific velocity — if you're expanding channels, do you have data from those channels?
- Cash position — can you absorb a slow period if the second run moves slower than expected?
- Remaining shelf life on current inventory — are you actually out of the first run, or are you sitting on unsold units?
If all of these check out, scale. If any of them raises a flag, run smaller and understand why before you commit more capital.
Ready to run your first batch?
Pricing from $2,750 flat. FDA registered. Same-day response.
Get a Quote →Get the full Real Runs co-packing playbook.
13 chapters covering everything from your first call to your first shipment — including the math that shows why a big MOQ is almost always a trap.
Download Free →